The most dangerous factors for pancreatitis after ERCP – systematic review with a prevention approach

Česká verze

Authors: Luděk Hrdlička
Authors place of work: ResTrial GastroEndo
Published in the journal: Gastroent Hepatol 2024; 78(4): 343-344
Category: Klinická a experimentální gastroenterologie: přehledová práce
doi: https://doi.org/10.48095/ccgh2024343

Zdroje

1. Baqai MT, Malik MN, Ziauddin F. Efficacy and safety of cinitapride in functional dyspepsia. J Pak Med Assoc 2013; 63 (6): 747–751.

2. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002; 50 (Suppl 4): 410–412. doi: 10.1136/gut.50.suppl_4.iv10.

3. Rome IV diagnostic criteria for disorders of gut-brain interaction (DGBI). 2016 [online]. Dostupné z: https: //theromefoundation.org/rome-iv/rome-iv-criteria/2016.

4. Moayyedi P, Lacy BE, Andrews CN et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 2017; 112 (7): 988–1013. doi: 10.1038/ajg.2017.154.

5. Yamasaki T, Hemond C, Eisa M et al. The changing epidemiology of gastroesophageal reflux dis ease: are patinets getting younger? J Neurogastroenterol Motil 2018; 24 (4): 559–569. doi: 10.5056/jnm18140.

6. Ren LH, Chen WX, Qian LJ et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux dis ease: a meta-analysis. World J Gastroenterol 2014; 20 (9): 2412–2419. doi: 10.3748/wjg.v20.i9.2412.

7. Hemalatha PV, Jerad Suresh A, Niraimathi V. Spectrophotometric methods for the estimation of cinitapride and pantoprazole in bulk and oral dosage form. ACAIJ 2013; 12 (1): 120–125.

8. Alarcón-de-la-Lastra Romero C, López A, Martín MJ et al. Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology 1997; 54 (4): 193–202. doi: 10.1159/000139487.

9. Alarcón de la Lastra C, La Casa C, Martin MJ et al. Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res 1998; 47 (3): 131–136. doi: 10.1007/s000110050301.

10. Portincasa P, Mearin F, Robert M et al. Efficacy and tolerability of cinitapride in the treatment of functional dyspepsia and delayed gastric emptying. Gastroenterol Hepatol 2009; 32 (10): 669–676. doi: 10.1016/j.gastrohep.2009.06.013.

11. Marcelínn-Jiménez G, Contreras L, Esquivel J et al. Development of an UPLC-MS/MS micromethod for quantitation of cinitapride inplasma and its application in a pharmacokinetic interaction trial. Bioanalysis 2017; 9 (6): 569–579. doi: 10.4155/bio -2016-0210.

12. Du Y, Su T, Song X et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol 2014; 48 (4): 328–335. doi: 10.1097/MCG.000000 0000000033.

13. Santos JG, Filpo F, López JM. Cinitapride’s efficacy and tolerability in gastrointestinal tract disorders. Navara University Medicine Magazine 1991.

14. Qi Q, Wang N, Liu H et al. Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis. BMC Gastroenterol 2023; 23 (1): 370. doi: 10.1186/s12876-023-03014-9.

15. Surós A, Adell F, De Novoa V et al. Cinitapride in the treatment of gastroesophageal reflux. Comparative study with metoclopramide and placebo. Rev Med Univ Navarra 1992; 37 (1): 18–23.

MUDr. Luděk Hrdlička

ResTrial GastroEndo

V Sadech 1081/4a

160 00 Praha 6

ludek.hrdlicka@restrial.com